Directorio

We are doing this study to learn more about what causes glioblastoma (GBM), a type of brain cancer, and the factors that affect GBM patients' quality of life. This research will help us to understand why some people get GBM, including how their genes and health history may contribute to tumor development and progression.

Some kids need a special tube called a central line to get medicine and food. But when the tube isn’t being used, it can get blocked or infected. To help stop this, doctors use a liquid called a locking solution. In this study, kids will be randomly placed into one of two groups: - Group 1 will use the regular locking liquid called heparin. - Group 2 will use a new liquid called Kitelock. Both groups will use their locking liquid every day. They’ll also have check-ups, blood tests, and keep a daily diary. The study will last about 1 year and include 6 in-person visits and 10 phone or video visits.

We are doing this study to find the most effective, safe dose of an experimental drug called ziftomenib (the study drug). We want to know how well it works when it combined with either standard non-intensive (venetoclax + azacitidine) therapy or standard intensive (7+3) therapy for adults who have acute myeloid leukemia.

We are doing this study to find the most effective, safe dose of an experimental drug called ziftomenib (the study drug). We want to know how well this study drug works in people with AML that have certain mutations in the NPM1 gene and rearrangements involving the KMT2A gene when it is given alone or in combination with other cancer drugs.

We are doing this study to find the most effective, safe dose of an experimental drug called ziftomenib (the study drug) to be used in combination with an established dose of imatinib for people who have advanced gastrointestinal stromal tumors (GIST) and failed treatment with imatinib on its own.

We are doing this study to compare 2 different surgeries for epithelial ovarian cancer. We want to know if an investigational surgical procedure called minimally invasive surgery can offer better results than the standard surgery, which is called laparotomy. We hope to find out if one procedure or the other is preferable when it comes to preventing cancer from returning and giving patients a better quality of life after their surgery.

We are doing this study to find out if a small dose (0.5 mg) of a drug called colchicine (the study drug) is beneficial for people with peripheral artery disease (PAD). We want to know if it has the potential to lower the risk of heart attack, stroke, and corrective leg surgeries for people who have PAD. The study drug is FDA-approved for the treatment of some inflammatory conditions (e.g., gout), but it is not approved for the treatment of PAD.

We are doing this study to support vaccine development by studying blood cells of the immune system.